In a murine non-alcoholic steatohepatitis (NASH) model, saroglitazar reduced the hepatic M1 macrophage infiltration by 40% and suppressed the NF-κB activity, highlighting its immunomodulatory potential beyond metabolic regulation [34,35,36,37]. Here, NFKB1 is linked to metabolic dysfunction-associated steatohepatitis.